DK1401869T3 - Molekyler og fremgangsmåder til inhibering af udskillkelse af kim 1 - Google Patents
Molekyler og fremgangsmåder til inhibering af udskillkelse af kim 1Info
- Publication number
- DK1401869T3 DK1401869T3 DK02734634T DK02734634T DK1401869T3 DK 1401869 T3 DK1401869 T3 DK 1401869T3 DK 02734634 T DK02734634 T DK 02734634T DK 02734634 T DK02734634 T DK 02734634T DK 1401869 T3 DK1401869 T3 DK 1401869T3
- Authority
- DK
- Denmark
- Prior art keywords
- methods
- excretion
- molecules
- inhibiting germ
- kim
- Prior art date
Links
- 230000029142 excretion Effects 0.000 title 1
- 230000002401 inhibitory effect Effects 0.000 title 1
- 102100034459 Hepatitis A virus cellular receptor 1 Human genes 0.000 abstract 3
- 101710185991 Hepatitis A virus cellular receptor 1 homolog Proteins 0.000 abstract 3
- 229920001184 polypeptide Polymers 0.000 abstract 2
- 102000004196 processed proteins & peptides Human genes 0.000 abstract 2
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 2
- 230000002797 proteolythic effect Effects 0.000 abstract 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5011—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing antineoplastic activity
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6854—Immunoglobulins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2500/00—Screening for compounds of potential therapeutic value
- G01N2500/02—Screening involving studying the effect of compounds C on the interaction between interacting molecules A and B (e.g. A = enzyme and B = substrate for A, or A = receptor and B = ligand for the receptor)
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Organic Chemistry (AREA)
- Cell Biology (AREA)
- Analytical Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Physics & Mathematics (AREA)
- Biotechnology (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Microbiology (AREA)
- Toxicology (AREA)
- Food Science & Technology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Tropical Medicine & Parasitology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US29544901P | 2001-06-01 | 2001-06-01 | |
| US29590701P | 2001-06-04 | 2001-06-04 | |
| PCT/US2002/017402 WO2002098920A1 (en) | 2001-06-01 | 2002-05-31 | Molecules and methods for inhibiting shedding of kim-1 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK1401869T3 true DK1401869T3 (da) | 2008-04-28 |
Family
ID=26969139
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK02734634T DK1401869T3 (da) | 2001-06-01 | 2002-05-31 | Molekyler og fremgangsmåder til inhibering af udskillkelse af kim 1 |
Country Status (10)
| Country | Link |
|---|---|
| US (3) | US7041290B2 (enExample) |
| EP (1) | EP1401869B1 (enExample) |
| JP (2) | JP4527394B2 (enExample) |
| AT (1) | ATE382060T1 (enExample) |
| AU (1) | AU2002305785B2 (enExample) |
| CA (1) | CA2448427C (enExample) |
| DE (1) | DE60224275T2 (enExample) |
| DK (1) | DK1401869T3 (enExample) |
| NZ (1) | NZ530457A (enExample) |
| WO (1) | WO2002098920A1 (enExample) |
Families Citing this family (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP4602482B2 (ja) * | 1996-05-24 | 2010-12-22 | バイオジェン・アイデック・エムエイ・インコーポレイテッド | 組織再生のモジュレーター |
| CA2412734A1 (en) * | 2000-06-16 | 2001-12-27 | Biogen, Inc. | Renal regulatory elements and methods of use thereof |
| EP1401869B1 (en) * | 2001-06-01 | 2007-12-26 | Biogen Idec MA Inc. | Molecules and methods for inhibiting shedding of kim-1 |
| AU2003228336B2 (en) * | 2002-03-19 | 2009-07-30 | Curagen Corporation | Therapeutic polypeptides, nucleic acids encoding same, and methods of use |
| AU2013205381B2 (en) * | 2002-03-19 | 2016-04-14 | Celldex Therapeutics, Inc. | Therapeutic polypeptides, nucleic acids encoding same, and methods of use |
| EP1585546B1 (en) * | 2002-12-30 | 2008-08-06 | Biogen Idec MA Inc. | Kim-1 antagonists and use to modulate immune system |
| EP3000886A1 (en) * | 2003-03-19 | 2016-03-30 | Amgen Fremont Inc. | Antibodies against t cell immunoglobulin domain and mucin domain 1 (tim-1) antigen and uses thereof |
| AU2013242840B2 (en) * | 2003-03-19 | 2017-01-19 | Amgen Fremont Inc. | Antibodies Against T Cell Immunoglobulin Domain and Mucin Domain 1 (TIM-1) Antigen and Uses Thereof |
| EP1532984A1 (en) * | 2003-11-19 | 2005-05-25 | Institut National De La Sante Et De La Recherche Medicale (Inserm) | Use of anti CD44 antibodies for eradicating stem cells in acute myeloid leukemia |
| KR101213894B1 (ko) | 2005-03-02 | 2012-12-20 | 바이오겐 아이덱 엠에이 인코포레이티드 | Ｔｈ2 매개성 병태를 치료하기 위한 ｋｉｍ-1 항체 |
| WO2007059082A1 (en) | 2005-11-10 | 2007-05-24 | Curagen Corporation | Method of treating ovarian and renal cancer using antibodies against t cell immunoglobulin domain and mucin domain 1 (tim-1) antigen |
| EP2894166A1 (en) | 2008-11-10 | 2015-07-15 | Alexion Pharmaceuticals, Inc. | Methods and compositions for treating complement-associated disorders |
| WO2011079280A2 (en) | 2009-12-23 | 2011-06-30 | Hill's Pet Nutrition, Inc. | Compositions and methods for diagnosing and treating kidney disorders in a canine |
| JP6012473B2 (ja) | 2010-01-11 | 2016-10-25 | アレクシオン ファーマシューティカルズ， インコーポレイテッド | 抗ｃｄ２００抗体を用いたヒトの処置における免疫調節効果のバイオマーカー |
| PL2563813T3 (pl) | 2010-04-30 | 2016-01-29 | Alexion Pharma Inc | Przeciwciała anty-C5a i sposoby stosowania przeciwciał |
| AU2012212066A1 (en) | 2011-02-03 | 2013-08-15 | Alexion Pharmaceuticals, Inc. | Use of an anti-CD200 antibody for prolonging the survival of allografts |
| US20150110792A1 (en) * | 2011-11-22 | 2015-04-23 | Biogen Idec Ma Inc. | ANTI-TIM-1 Antibodies And Uses Thereof |
| WO2015023836A1 (en) * | 2013-08-16 | 2015-02-19 | The Brigham And Women's Hospital, Inc. | Kim-1 as a therapeutic target in conditions associated with kidney fibrosis |
| US10712349B2 (en) | 2014-04-15 | 2020-07-14 | The Brigham And Women's Hospital, Inc. | Circulating KIM-1 levels for detection of pathologies associated with injury to, or cancer of, the kidney |
| EP3568416A4 (en) * | 2017-01-13 | 2020-07-08 | Celdara Medical, LLC | TIM-1 TARGETED CHIMERIC ANTIGENIC RECEPTORS |
| EP3615510B1 (en) | 2017-04-28 | 2024-03-27 | Acuitas Therapeutics, Inc. | Novel carbonyl lipids and lipid nanoparticle formulations for delivery of nucleic acids |
| WO2020061426A2 (en) | 2018-09-21 | 2020-03-26 | Acuitas Therapeutics, Inc. | Systems and methods for manufacturing lipid nanoparticles and liposomes |
| DK3908568T3 (da) | 2019-01-11 | 2024-08-26 | Acuitas Therapeutics Inc | Lipider til lipidnanopartikellevering af aktivstoffer |
| US11976019B2 (en) | 2020-07-16 | 2024-05-07 | Acuitas Therapeutics, Inc. | Cationic lipids for use in lipid nanoparticles |
| KR20240123832A (ko) | 2021-12-16 | 2024-08-14 | 아퀴타스 테라퓨틱스 인크. | 지질 나노입자 제형에 사용하기 위한 지질 |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5622861A (en) | 1994-08-05 | 1997-04-22 | The United States Of America As Represented By The Department Of Health And Human Services | Recombinant DNA encoding hepatitis A virus receptor |
| JP4602482B2 (ja) * | 1996-05-24 | 2010-12-22 | バイオジェン・アイデック・エムエイ・インコーポレイテッド | 組織再生のモジュレーター |
| CA2412734A1 (en) * | 2000-06-16 | 2001-12-27 | Biogen, Inc. | Renal regulatory elements and methods of use thereof |
| EP1401869B1 (en) * | 2001-06-01 | 2007-12-26 | Biogen Idec MA Inc. | Molecules and methods for inhibiting shedding of kim-1 |
| US7838220B2 (en) * | 2001-06-29 | 2010-11-23 | The Board Of Trustees Of The Leland Stanford Junior University | T cell regulatory genes associated with immune disease |
| EP1406653A4 (en) * | 2001-06-29 | 2005-05-04 | Univ Leland Stanford Junior | T CELL REGULATION GENES AND METHOD OF USE THEREOF |
| CA2459219A1 (en) | 2001-09-17 | 2003-03-27 | Protein Design Labs, Inc. | Methods of diagnosis of cancer compositions and methods of screening for modulators of cancer |
| WO2003042661A2 (en) | 2001-11-13 | 2003-05-22 | Protein Design Labs, Inc. | Methods of diagnosis of cancer, compositions and methods of screening for modulators of cancer |
| US7687454B2 (en) * | 2001-12-03 | 2010-03-30 | The University Of British Columbia | Effectors of innate immunity determination |
| EP3020413A1 (en) * | 2002-01-30 | 2016-05-18 | The Brigham and Women's Hospital, Inc. | Compositions and methods related to TIM-3, a TH1-specific cell surface molecule |
| AU2003228336B2 (en) | 2002-03-19 | 2009-07-30 | Curagen Corporation | Therapeutic polypeptides, nucleic acids encoding same, and methods of use |
| GB0215509D0 (en) | 2002-07-04 | 2002-08-14 | Novartis Ag | Marker genes |
| EP3000886A1 (en) | 2003-03-19 | 2016-03-30 | Amgen Fremont Inc. | Antibodies against t cell immunoglobulin domain and mucin domain 1 (tim-1) antigen and uses thereof |
| WO2005001092A2 (en) | 2003-05-20 | 2005-01-06 | Wyeth | Compositions and methods for diagnosing and treating cancers |
-
2002
- 2002-05-31 EP EP02734634A patent/EP1401869B1/en not_active Expired - Lifetime
- 2002-05-31 AT AT02734634T patent/ATE382060T1/de not_active IP Right Cessation
- 2002-05-31 CA CA2448427A patent/CA2448427C/en not_active Expired - Fee Related
- 2002-05-31 JP JP2003502040A patent/JP4527394B2/ja not_active Expired - Fee Related
- 2002-05-31 DK DK02734634T patent/DK1401869T3/da active
- 2002-05-31 AU AU2002305785A patent/AU2002305785B2/en not_active Ceased
- 2002-05-31 NZ NZ530457A patent/NZ530457A/en not_active IP Right Cessation
- 2002-05-31 DE DE60224275T patent/DE60224275T2/de not_active Expired - Lifetime
- 2002-05-31 WO PCT/US2002/017402 patent/WO2002098920A1/en not_active Ceased
-
2003
- 2003-11-20 US US10/718,321 patent/US7041290B2/en not_active Expired - Lifetime
-
2006
- 2006-02-07 US US11/349,852 patent/US7300652B2/en not_active Expired - Lifetime
-
2007
- 2007-10-30 US US11/929,289 patent/US7696321B2/en not_active Expired - Lifetime
-
2010
- 2010-03-24 JP JP2010068988A patent/JP2010150291A/ja not_active Withdrawn
Also Published As
| Publication number | Publication date |
|---|---|
| US7300652B2 (en) | 2007-11-27 |
| JP2010150291A (ja) | 2010-07-08 |
| EP1401869B1 (en) | 2007-12-26 |
| CA2448427C (en) | 2013-09-24 |
| JP2005505256A (ja) | 2005-02-24 |
| JP4527394B2 (ja) | 2010-08-18 |
| DE60224275D1 (de) | 2008-02-07 |
| EP1401869A1 (en) | 2004-03-31 |
| US7696321B2 (en) | 2010-04-13 |
| DE60224275T2 (de) | 2008-12-11 |
| AU2002305785B2 (en) | 2008-01-17 |
| EP1401869A4 (en) | 2005-10-19 |
| US20080124336A1 (en) | 2008-05-29 |
| ATE382060T1 (de) | 2008-01-15 |
| CA2448427A1 (en) | 2002-12-12 |
| WO2002098920A1 (en) | 2002-12-12 |
| US20060153836A1 (en) | 2006-07-13 |
| NZ530457A (en) | 2007-12-21 |
| US7041290B2 (en) | 2006-05-09 |
| US20050112117A1 (en) | 2005-05-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DK1401869T3 (da) | Molekyler og fremgangsmåder til inhibering af udskillkelse af kim 1 | |
| DK1211361T3 (da) | Momentmodstående stropforbindelse | |
| DK1261368T3 (da) | Tværbunden, ikke-fungal lipaseholdig sammensætning og fremgangsmåder til anvendelse deraf | |
| DE60128652D1 (de) | Prostatischer stent zur erleichterung der drainage | |
| DE69939864D1 (de) | Ppar-gamma modulatoren | |
| TR200602095T2 (tr) | Hümanize Anti-LT-Beta-R antikorları | |
| DK2258168T3 (da) | Apparat til isolering af X-kromosombærende og Y-kromosombærende populationer af spermatozoer | |
| DK1276551T3 (da) | Kompositmembran og fremgangsmåde til fremstilling af samme | |
| DK1553975T3 (da) | Optimerede Fc-varianter og fremgangsmåder til generering heraf. | |
| DK2322603T3 (da) | Sammensætninger og fremgangsmåder til aktivering af monocytiske dendritiske celler og t-celler for th1-respons | |
| DK1066049T3 (da) | Farmaceutiske præparater, der er beregnet til langvarig frigivelse af peptider og fremgangsmåde til fremstilling af disse | |
| DE60220529D1 (de) | Quantisiertes förderungssystem für 'solid free form fabrication' | |
| DK0833839T3 (da) | Heterocykliske peptidylforbindelser, der er nyttige til behandling af thrombinrelaterede sygdomme | |
| DK1352895T3 (da) | Adamantanderivater til behandling af inflammatioriske immunologiske og kardiovaskulære sygdomme | |
| DK1437966T3 (da) | Måling af proteinsyntesehastigheder hos mennesker og i forsøgssystemer ved anvendelse af isotopisk mærket vand | |
| CY1116768T1 (el) | Συνθεσεις οι οποιες περιεχουν βλαστοκυτταρα θηλυκης γαμετικης σειρας και μεθοδοι χρησης αυτων | |
| DE60137015D1 (de) | Verdichteranlage | |
| DK1184474T3 (da) | Fremgangsmåde til fremstilling af meget tynde bånd i aluminium-jern-legering | |
| MA30265B1 (fr) | Procedes et compositions destines a cibler relt | |
| ATE298471T1 (de) | Zweidimensionale pyramidenfilterarchitektur | |
| DE60139893D1 (de) | Neue fructosyl-aminosäureoxidase | |
| DK1316239T3 (da) | Höreapparat og fremgangsmåde til fremstilling af samme | |
| DK1318142T3 (da) | t-butoxycarbonylaminoethylamin til syntese af PNA-monomerenheder, aminosyrederivater, mellemprodukter deraf og fremgangsmåder til fremstilling af disse | |
| LU90968B1 (de) | Schlackengranulierungsanlage | |
| DK1194158T3 (da) | Anvendelse af UK 114-proteiner til hæmning af organtransplantatafstödning |